Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal
by Zacks Equity Research
Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.
Vertex's (VRTX) Non-Opioid Pain Drug Meets Primary Goal
by Zacks Equity Research
Three late-stage studies data show that Vertex's (VRTX) experimental non-opioid drug reduced pain across a 48-hour period. Based on this data, VRTX intends to submit an FDA filing by mid-2024.
Stay Ahead of the Game With Vertex (VRTX) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Vertex (VRTX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here's Why
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $435.82 in the latest trading session, marking a +1.31% move from the prior day.
PBYI or VRTX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBYI vs. VRTX: Which Stock Is the Better Value Option?
Wall Street Bulls Look Optimistic About Vertex (VRTX): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Vertex Pharmaceuticals (VRTX) Stock Dips While Market Gains: Key Facts
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) reachead $439.70 at the closing of the latest trading day, reflecting a -0.09% change compared to its last close.
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
by Zacks Equity Research
Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $433.76, signifying a -0.85% move from its prior day's close.
Vertex (VRTX), CRSP's Casgevy Gets FDA Nod for Thalassemia
by Zacks Equity Research
This is the second approval granted to Vertex (VRTX)/CRISPR's (CRSP) gene therapy Casgevy and comes just a month after the FDA approved the therapy for sickle cell disease.
Here's How Much You'd Have If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Vertex Pharmaceuticals (VRTX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $421.01, indicating a +0.45% shift from the previous trading day.
What Makes Vertex Pharmaceuticals (VRTX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Vertex Pharmaceuticals (VRTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Will Vertex (VRTX) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
PBYI vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBYI vs. VRTX: Which Stock Is the Better Value Option?
Vertex Pharmaceuticals (VRTX) Stock Moves -0.05%: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $410.71, signifying a -0.05% move from its prior day's close.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why
by Zacks Equity Research
Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Vertex.
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $409.27, indicating a +0.3% shift from the previous trading day.
The Zacks Analyst Blog Highlights Alphabet, Comcast, NextEra, Vertex and Eni
by Zacks Equity Research
Alphabet, Comcast, NextEra, Vertex and Eni are included in this Analyst Blog.
Top Analyst Reports for Alphabet, Comcast & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Comcast Corp. (CMCSA) and NextEra Energy, Inc. (NEE).
Vertex Pharmaceuticals (VRTX) Stock Moves -0.72%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $400.25, marking a -0.72% move from the previous day.
bluebird (BLUE) Stock Down on Raising Additional Capital
by Zacks Equity Research
bluebird (BLUE) issues shares to raise capital to support the commercialization and manufacturing of its three approved gene therapies. Its shares are down on the dilution of equity.